Overview
Shares of agilon health Inc. climbed dramatically in morning trading, rising 74.09% to $48.49 after the company released first-quarter 2026 results following the market close on May 6. The gains came after the company posted results that outpaced analyst expectations across the key financial metrics and issued a notable upward revision to its full-year 2026 guidance.
Quarterly results in detail
agilon reported quarterly revenue of $1.42 billion, ahead of the analyst consensus of $1.38 billion. GAAP earnings per share came in at $1.80, far surpassing the consensus estimate of $0.83. Adjusted EBITDA was reported at $53.84 million, topping the expected $36.15 million by nearly 49%.
Alongside the results, management raised its 2026 full-year outlook. Adjusted EBITDA guidance was lifted to a range of $10 million to $40 million, up from the prior ($15) to $15 million band. Medical margin guidance was also increased to $350 million to $400 million.
Management commentary
Executive Chairman Ronald A. Williams framed the quarter and the guidance raise as a product of disciplined execution and movement against strategic priorities. He said,
"Our strong first-quarter performance and increase in full-year 2026 guidance reflects disciplined execution and progress against our strategic priorities. We are seeing early returns from investments in data and technology, clinical execution, and operating discipline."
Analyst reaction and price targets
The earnings surprise and guidance improvement prompted a wave of analyst upgrades. Deutsche Bank raised its rating on the stock to Buy from Hold and set a $49.00 price target. Jefferies moved its rating to Buy from Hold and increased its price target to $48.00, citing clearer trend visibility and Medicare Advantage rates locked in for 2026 and 2027. Jefferies analyst Jack Slevin highlighted that 85% of lives are now in the company's data pipeline as a factor supporting the more positive outlook.
Bernstein SocGen, by contrast, kept a Market Perform rating while noting 2026 should be a year of recovery for Medicare Advantage plans and that recovery could extend to value-based care participants. That firm saw the company’s results as outperformance with potential for further upside as 2026 Medicare Advantage reserves develop.
Leadership transition
Today is also the first official day for new CEO Tim O'Rourke. The company described O'Rourke as an executive with significant payer and provider experience and a deep understanding of what is required to succeed in value-based care. The company said O'Rourke is committed to advancing the firm’s mission and strategy.
Operational drivers cited
Company commentary and the earnings detail attributed outperformance to improved risk scores, tighter cost management and the addition of a new full-risk contract. Management pointed to early returns on investments in data and technology, stronger clinical program execution, improved payer contracting and higher utilization of the data pipeline as reasons for the higher medical margin and Adjusted EBITDA results and for the upward revision to full-year guidance.
Market context and stock action
The broader U.S. market was essentially neutral during the move, with the S&P 500 virtually unchanged at -0.01%, the Dow Jones down -0.07% and the NASDAQ modestly higher at +0.27%. That muted market backdrop underscores that agilon health’s substantial intraday gain was driven by company-specific developments.
During the session the stock reached a high of $52.38 and was trading well above its 52-week low of $7.48, marking what market participants described as a significant shift in sentiment toward the value-based care platform.
Conclusion
The combination of an outsized quarterly beat, a broad guidance raise, several analyst upgrades and the start of new CEO leadership produced a rare confluence of positive catalysts for agilon health. Management and analysts have pointed to operational improvements and expanding use of data assets as the main drivers behind the quarter’s results and the more optimistic outlook for 2026.